EMEA-001460-PIP01-13-M05
Key facts
| Invented name |
Genvoya
|
| Active substance |
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0435/2020
|
| PIP number |
EMEA-001460-PIP01-13-M05
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Gilead Sciences International Ltd
Tel. +44 (0)1223 897300 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001460-PIP01-13-M05
|
| Compliance opinion date |
25/06/2021
|
| Compliance outcome |
positive
|